Abstract
Objective To describe the implementation of a test-negative design case-control study in California during the Coronavirus Disease 2019 (COVID-19) pandemic.
Methods Between February 24, 2021 - February 24, 2022, 34 interviewers called 38,470 SARS-CoV-2-tested Californians to enroll 1,885 cases and 1,871 controls in a 20-minute telephone survey. We estimated adjusted odds ratios for answering the phone and consenting to participate using mixed effects logistic regression. We used a web-based anonymous survey to compile interviewer experiences.
Results Cases had 1.29-fold (95% CI: 1.24–1.35) higher adjusted odds of answering the phone and 1.69-fold (1.56–1.83) higher adjusted odds of consenting to participate compared to controls. Calls placed from 4pm to 6pm had the highest adjusted odds of being answered. Interviewers who faced participants with dire need for social services or harassment experienced poor mental health.
Conclusions We suggest calling during afternoons and allocating more effort towards enrolling controls when designing a case-control study. Remaining adaptive to the dynamic needs of the team is critical to a successful study, especially in a pandemic setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Centers for Disease Control and Prevention, Epidemiology and Laboratory Capacity (ELC) building grant (number 5-NU50CK000539).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the State of California, Health and Human Services Agency, Committee for the Protection of Human Subjects (Project Number: 2021-034).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵§ Members of the California COVID-19 Case-Control Study Team include: Adrian Cornejo, Amanda Lam, Amanda Moe, Amandeep Kaur, Anna Fang, Ashly Dyke, Camilla Barbaduomo, Christine Wan, Diana Nicole Morales Felipe, Diana Poindexter, Erin Xavier, Hyemin Park, Helia Samani, Jessica Ni, Julia Cheunkarndee, Mahsa Javadi, Maya Spencer, Michelle Spinosa, Miriam Bermejo, Monique Miller, Najla Dabbagh, Natalie Dassian, Nikolina Walas, Paulina Frost, Savannah Corredor, Shrey Saretha, Timothy Ho, Vivian Tran, Yang Zhou, Yasmine Abdulrahim, Zheng Dong
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
